Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Murrell

Showing results (431-440 of 491) with videos related to

Pageof 50
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2024
The development and validation of an investigator global assessment score for keratosis pilarisMadeline A Wang, Anna Wilson, Darby Boucher, et al.
Veterinary Dermatology|January 4, 2020
Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceusElizabeth C Goodale, Katarina E Varjonen, Catherine A Outerbridge, et al.
The British Journal of Dermatology|September 3, 2017
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statementA M Drucker, K Eyerich, M S de Bruin-Weller, et al.
Journal of Cell Science|December 21, 2013
Type VII collagen regulates expression of OATP1B3, promotes front-to-rear polarity and increases structural organisation in 3D spheroid cultures of RDEB tumour keratinocytesJasbani H S Dayal, Clare L Cole, Celine Pourreyron, et al.
The Journal of Investigative Dermatology|August 15, 2014
From epidemiology and genetics to diagnostics, outcome measures, and novel treatments in autoimmune bullous diseasesRalf J Ludwig, Luca Borradori, Luis A Diaz, et al.
Journal of the American Academy of Dermatology|October 1, 2013
A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosaSupriya S Venugopal, Wenfei Yan, John W Frew, et al.
The British Journal of Dermatology|October 10, 2013
The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering diseaseA Tjokrowidjaja, B S Daniel, J W Frew, et al.
Veterinary Dermatology|August 18, 2020
Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceusElizabeth C Goodale, Stephen D White, Petra Bizikova, et al.
The Journal of Dermatology|March 20, 2025
Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnairesChika Tanemura, Maya Nunotani, Kyoko Kawabata, et al.
The British Journal of Dermatology|October 23, 2021
Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guidelineD T Greenblatt, E Pillay, K Snelson, et al.
Pageof 50

Showing results (431-440 of 491) with videos related to

Sort By:
Pageof 50
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2024
The development and validation of an investigator global assessment score for keratosis pilarisMadeline A Wang, Anna Wilson, Darby Boucher, et al.
Veterinary Dermatology|January 4, 2020
Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceusElizabeth C Goodale, Katarina E Varjonen, Catherine A Outerbridge, et al.
The British Journal of Dermatology|September 3, 2017
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statementA M Drucker, K Eyerich, M S de Bruin-Weller, et al.
Journal of Cell Science|December 21, 2013
Type VII collagen regulates expression of OATP1B3, promotes front-to-rear polarity and increases structural organisation in 3D spheroid cultures of RDEB tumour keratinocytesJasbani H S Dayal, Clare L Cole, Celine Pourreyron, et al.
The Journal of Investigative Dermatology|August 15, 2014
From epidemiology and genetics to diagnostics, outcome measures, and novel treatments in autoimmune bullous diseasesRalf J Ludwig, Luca Borradori, Luis A Diaz, et al.
Journal of the American Academy of Dermatology|October 1, 2013
A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosaSupriya S Venugopal, Wenfei Yan, John W Frew, et al.
The British Journal of Dermatology|October 10, 2013
The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering diseaseA Tjokrowidjaja, B S Daniel, J W Frew, et al.
Veterinary Dermatology|August 18, 2020
Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceusElizabeth C Goodale, Stephen D White, Petra Bizikova, et al.
The Journal of Dermatology|March 20, 2025
Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnairesChika Tanemura, Maya Nunotani, Kyoko Kawabata, et al.
The British Journal of Dermatology|October 23, 2021
Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guidelineD T Greenblatt, E Pillay, K Snelson, et al.
Pageof 50